Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab

References

• Gurram M, Pahwa S, Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy. 1994;73: 493–496.
   PubMedGoogle Scholar
• Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol. 1992;19: 1207–1211.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol. 1998;25: 308–313.
   PubMed Web of Science ®Google Scholar
• Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001;27: 140–146
   PubMed Web of Science ®Google Scholar
• Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, Ong VH. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis. 2012 [Epub ahead of print].
   Web of Science ®Google Scholar
• Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest. 1999;103: 1253–1260
   PubMed Web of Science ®Google Scholar
• Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T, Arimitsu J, Narazaki M, Hagihara K, Ogata A, Katayama I, Kawase I, Kishimoto T, Tanaka T. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford). 2010;49: 2408–2412
   PubMed Web of Science ®Google Scholar
• Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, Ohmann C, Gensch K, Ruzicka T. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford). 2010;49: 1336–1345
   PubMed Web of Science ®Google Scholar
• Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol. 2004;22: S87–S89.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthr Rheum. 1998;41: 1613–1619
   PubMed Web of Science ®Google Scholar
• Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W et al. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthr Rheum. 1999;42: 1194–1203
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C et al. EULAR recommendations for the treatment of systemic sclerosis a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68: 620–628
   PubMed Web of Science ®Google Scholar
• Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O’Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthr Rheum. 2001;44: 1351–1358
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354: 2655–2666
   PubMed Web of Science ®Google Scholar
• Plotz PH, Klippel JH, Decker JL, Grauman D, Wolff B, Brown BC, Rutt G. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med. 1979;91: 221–223.
   PubMed Web of Science ®Google Scholar
• Filaci G, Cutolo M, Scudeletti M, Castagneto C, Derchi L, Gianrossi R, Ropolo F, Zentilin P, Sulli A, Murdaca G, Ghio M, Indiveri F, Puppo F. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford). 1999;38: 992–996
   PubMed Web of Science ®Google Scholar
• Denton CP, Sweny P, Abdulla A, Black CM. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol. 1994;33: 90–92
   PubMedGoogle Scholar
• Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford). 2001;40: 84–88
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis–a retrospective analysis. Rheumatology (Oxford). 2007;46: 442–445
   PubMed Web of Science ®Google Scholar
• Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012;39: 1241–1247
   PubMed Web of Science ®Google Scholar
• Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, Carreira PE, Diaz Gonzalez F, Black CM, Hoogen FH. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009;68: 1433–1439
   PubMed Web of Science ®Google Scholar
• McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford). 2008;47: 552–553
   PubMed Web of Science ®Google Scholar